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Abstract
Background: Hydrodilatation of the glenohumeral joint is by several authors reported to improve
shoulder pain and range of motion for patients with adhesive capsulitis. Procedures described often
involve the injection of corticosteroids, to which the reported treatment effects may be attributed.
Any important contribution arising from the hydrodilatation procedure itself remains to be
demonstrated.
Methods: In this randomized trial, a hydrodilatation procedure including corticosteroids was
compared with the injection of corticosteroids without dilatation. Patients were given three
injections with two-week intervals, and all injections were given under fluoroscopic guidance.
Outcome measures were the Shoulder Pain and Disability Index (SPADI) and measures of active
and passive range of motion. Seventy-six patients were included and groups were compared six
weeks after treatment. The study was designed as an open trial.
Results: The groups showed a rather similar degree of improvement from baseline. According to
a multiple regression analysis, the effect of dilatation was a mean improvement of 3 points
(confidence interval: -5 to 11) on the SPADI 0–100 scale. T-tests did not demonstrate any
significant between-group differences in range of motion.
Conclusion: This study did not identify any important treatment effects resulting from three
hydrodilatations that included steroid compared with three steroid injections alone.
Trial registration: The study is registered in Current Controlled Trials with the registration
number ISRCTN90567697.
Background
Adhesive capsulitis is a common cause of shoulder pain
and disability. It is characterized by a usually spontaneous
onset of shoulder pain accompanied by progressive limi-
tation of both active and passive glenohumeral move-
ment. Both pain and stiffness tend to resolve
spontaneously over months to years [1-4]. In 1945, Nevi-
aser reported that the essential pathology of the condition
"is a thickening and contraction of the capsule which
becomes adherent to the humeral head" [5], thus causing
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recent arthroscopic investigations of frozen shoulder
patients report no distinct intraarticular adhesions of this
type [6-9], and the role of such adhesions is unclear. The
finding of contractions of the joint capsule is supported
though, as the studies describe a marked reduction in
joint volume [6-9] due to contraction of collagenous tis-
sue surrounding the joint [7].
During the decades following Neviaser's discovery, tech-
niques were developed in order to loosen the reported
contraction and adhesion. Distension arthrography (also
known as hydrodilatation) is one of these techniques. It is
in principle an injection into the glenohumeral joint
under pressure. The hydrodilatation procedure was first
described by Andrèn and Lundberg [10]. Since then, a
number of investigators have studied the effects of
hydrodilatation treatment, and several report beneficial
results [11-21]. However, due to various weaknesses in
study design, most of these studies are of limited value as
evidence for a specific treatment effect from hydrodilata-
tion. First and foremost, few of the studies claiming a
treatment effect are randomized trials involving some sort
of control group. Because these patients tend to recover
spontaneously, a control group is essential in order to
claim a treatment effect from the intervention. Secondly,
treatment given in these studies was rarely restricted to
mere hydrodilatation. Some interventions included a
physiotherapy program or manipulation procedures.
Most investigators used corticosteroids in addition to the
dilatation procedure, and this may be important. Some
studies investigating the effect of intraarticular steroids
without dilatation have reported quicker improvement in
pain in treated groups [22-24]. Rather similar treatment
effects of oral corticosteroids have been found [25,26]. It
is possible that the reported beneficial effects of the com-
bined hydrodilatation/corticosteroid procedure rely on a
corticosteroid effect, thus giving the dilatation part of the
procedure unclear value.
No randomized trials have compared distension alone
with placebo. The combined intervention of steroid injec-
tion and distension has been compared with steroid injec-
tion in three studies so far [15,27,28]. The study by Jacobs
et al. [28] included a dilatation procedure injecting only a
maximum of 10 ml, which is less than most other investi-
gators have used. It is unclear whether this volume is suf-
ficient to cause an effective distension of the joint capsule.
In the two other studies, a volume of 20 ml was used in
the distension groups. These studies were too small to
conclude whether there was an additional treatment effect
of the hydrodilatation procedure or not. The largest study
had 45 patients available for analysis [13].
The aim of the present study is to investigate if the effect
of dilatation represents an important contribution to
overall treatment effects of a combined dilatation/steroid
injection procedure.
Methods
We conducted a randomized trial and compared the effi-
cacy of hydrodilatation plus corticosteroid injection with
the efficacy of corticosteroid injection without dilatation.
In this way, we wanted to test the null hypothesis that nei-
ther of the interventions is superior to the other. The
regional ethics committee granted ethical approval. The
procedures followed protocol and complied with the Hel-
sinki Declaration as revised in 1983 and current national
ethical standards for such trials.
Participants
Patients referred to the Ullevål University Hospital's
Department of Physical medicine and Rehabilitation in
the time period Dec. 1 2003 – June 1 2005 were consid-
ered for the study. Patients were assessed for eligibility
according to the following criteria:
1. Limitation of passive movement in the glenohumeral
joint compared with the unaffected side, more than 30
degrees for at least two of these three movements: forward
flexion, abduction or external rotation. Patients with pre-
vious adhesive capsulitis in the opposite shoulder were
accepted even if the differences between sides were some-
what smaller than 30 degrees. Patients were not eligible if
they could not comply with range of motion measure-
ment procedures due to e.g. excessive pain during meas-
urements or huge difficulties in relaxing sufficiently to
allow the investigator to make adequate recordings.
2. Pain in predominantly one shoulder lasting for more
than 3 months, less than 2 years.
3. Willingness and ability to fill out shoulder self-report
form.
The patients were included after informed consent unless
they met any of the following criteria:
1. Unwillingness to participate in the trial.
2. Diabetes mellitus (DM). In our pilot study, we experi-
enced problems for some DM patients in regulating blood
sugar levels on the days following the injections. A study
has shown that hydrodilatation may be less beneficial in
diabetic patients [29]. All patients with DM were excluded
from the study.
3. Trauma to the shoulder the last six months that
required hospital care. We expected that patients withPage 2 of 10
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and that this could cause problems when interpreting
overall results.
4. Serious mental illness.
5. Age under 18 or over 70.
6. Various contraindications to injections: allergy to injec-
tion material, blood coagulation disorders.
7. Patients with cancer and patients not expected to be
able to follow treatment or follow-up protocol for practi-
cal or other reasons.
8. Patients currently taking corticosteroid tablets.
9. Reduction of glenohumeral range of motion for reasons
other than "classic" adhesive capsulitis, e.g. X-ray signs of
glenohumeral arthritis, dislocation or full-thickness rota-
tor cuff tears with displacement of the humeral head.
Details of inclusion are given in Figure 1. 76 patients were
included.
Randomization
Randomization took place after baseline information had
been gathered. Patients were randomized to one of the
following interventions:
1. Injection (INJ) of a corticosteroid, a contrast agent and
a local anesthetic.
2. Dilatation (DIL) with a corticosteroid, a contrast agent,
local anesthetic plus saline necessary to obtain a dilata-
tion and rupturing of the joint capsule.
Three injections with two-week intervals were planned for
each patient. Randomization and allocation of patients
was conducted on a patient-by-patient basis by an inde-
pendent person (researcher) using the "minimization"
method [30], with "loaded dice". Minimization was pre-
ferred to purely random allocation in order to reduce
group differences at baseline. The chance of being allo-
cated to a certain intervention group varied from 1/6 to 5/
6 depending on initial SPADI [31] scores (stratifying for
SPADI = 50 or SPADI > 50) and the number of patients
already allocated to each intervention. 11 patients (30%)
in the INJ group and 14 patients (36%) in the DIL group
had baseline SPADI = 50. Patients were not informed of
their actual assignments until the first injection was to be
given. The randomization procedure was successful in the
sense that it was followed according to protocol. Patient
demographic and clinical characteristics at baseline are
given in Table 1. Since we did not suspect any problems
with the randomization, no baseline tests of imbalance
were performed [32].
Interventions
The steps of the injection and dilatation procedures were
documented with repeated X-ray examinations. The inter-
vention procedures were as follows:
INJ
Arthrograms were performed according to the Kaye-Sch-
neider technique [33]. The patients were placed supine on
a table with an overhead X-ray tube and a supporting pil-
low under the opposite shoulder. Under image-intensi-
fied fluoroscopy a marker was placed over the
glenohumeral joint space at about the junction of its mid-
dle and lower third. This point was then marked on the
skin with a pen. The skin area was cleaned with an anti-
septic. The joint was punctured by a needle (22 G intra-
muscular needle) and its position was checked frequently
by fluoroscopy during the procedure. The needle was con-
nected via a short tube to the syringe. An injection of 3–4
ml contrast medium (lopromide, Ultravist 300 Schering
AG), 2 ml triamcinolone acetonide (Kenacort 10 mg/ml,
Bristol-Myers Squibb) and 3–4 ml of local anesthetic
(bupivacaine hydrochloride, Marcain 5 mg/ml, Astra-
Zeneca) was given slowly, controlling visually that all
fluid was injected into the joint.
DIL
When performing these injections, the syringe was filled
with 4 ml of contrast medium, 2 ml triamcinolone aceto-
nide, 4 ml local anesthetic and 10 ml saline. This injection
of 20 ml in total was given to all patients undergoing the
dilatation treatment. The fluid was injected very slowly
into the joint. When resistance was met, injection was
halted for a while, and then continued. During the injec-
tion, the joint was gradually distended, making especially
the axillar and subscapular recesses more visible. The cap-
sule would usually rupture in the wall of the subscapular
recess, or sometimes in the wall of the bicipital or axillary
recesses. This was recorded as a loss of resistance and con-
trast leakage was identified by fluoroscopy. If rupture had
not occurred, more Ultravist/Marcain was injected until
rupture. The needle was then ejected. Rupture occurred in
all patients but one belonging to the dilatation group.
Rupture also occurred in four of the patients belonging to
the injection group, even though the injection volume
was kept as low as possible to prevent this. The volume
given was judged to be necessary to inject corticosteroid,
local anesthetic and contrast material sufficient to confirm
the injection site. Mean volumes injected in the INJ group
on the three occasions were 8 ml (SD:4), 7 ml (SD:2) and
7 ml (SD:2). The overall mean in this group was 7 ml
(SD:3). Mean volumes in the DIL group were 21 mlPage 3 of 10
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Patient flowFigure 1
Patient flow.
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BMC Musculoskeletal Disorders 2008, 9:53 http://www.biomedcentral.com/1471-2474/9/53(SD:3), 20 ml (SD:1) and 21 ml (SD:2). Overall mean was
21 ml (SD:2). The number of patients in the DIL group
who received more than 20 ml were 8, 3 and 4 on each of
the three occasions.
At baseline, some patients were taking oral medication for
shoulder pain, usually acetaminophen or various
NSAIDs. A few were receiving physiotherapy to improve
their shoulder condition. Patients were not instructed to
attend to any specific physiotherapy program or manipu-
lation procedure, but were allowed to proceed with their
current treatment program if they wished. No patients
were prescribed new physiotherapy programs during the
study. Pain medication, physiotherapy and sick leave dur-
ing the study were organized by the patients' primary care
clinicians who were not informed of the patients' treat-
ment allocation.
Follow-up and assessment of outcome
The following parameters were chosen as outcome meas-
ures and registered at baseline (inclusion) and at follow-
up, 6 weeks after the last injection:
1. SPADI score. SPADI is a self-administered instrument
that measures pain and disability associated with shoul-
der disease [31]. It consists of five pain and eight disability
items each measured on a visual analogue scale. Pain and
disability subscales are calculated as the mean of the cor-
responding items on a 0–100 scale, the highest score indi-
cating the most severe pain and disability. The total score
is calculated as the average of the pain and disability sub-
scales. The score used in our study was a Norwegian ver-
sion [34], translated according to internationally accepted
guidelines [35]. SPADI has been used in previous rand-
omized trials investigating treatment effects in frozen
shoulder populations [11,23,26]. Psychometric proper-
ties of the index have been tested in shoulder patients and
indicate acceptable validity for group comparisons [36-
38].
2. Active and passive range of motion (AROM and
PROM). Measurements of range of motion (ROM) were
made in four different directions of movement: forward
flexion and abduction from neutral (patient standing)
and external/internal rotation from a position of approxi-
mately 45° of abduction (patient in supine position).
PROM measurements were performed with scapula man-
ually stabilized and end-point was determined at the
point where resistance to the movement was felt and
before the scapula began to move (aiming to measure
glenohumeral ROM). For active movements, the patient
was instructed to move the arm as far as possible in the
requested direction with minimal additional movement.
Scapular movement was not restricted, meaning that total
shoulder ROM in each direction was measured in this case.
The reliability of ROM measurements was estimated (sep-
arate study) and ICC ranged from 0.61 to 0.93 for the var-
ious movements. A Cybex Electronic Digital Inclinometer
(EDI 320, Cybex Inc., Ronkonkoma, NY) was used.
No specific treatment was planned between the injections
or between the last injection and follow-up. All data was
recorded by Nov. 1 2005. Follow-up measurements were
made by the same independent person, who was experi-
enced in range of motion measurements. The study was
an open trial where neither participants nor outcome
assessors were blinded.
Statistical analyses
Analyses were conducted according to the intention-to-
treat (ITT) principle [39]. Linear regression analysis [40]
was used to compare SPADI score improvement in the
two treatment groups. This type of analysis was chosen
according to recommendations for controlling for base-
line differences when reporting results from randomized
trials [41,42]. According to the recommendations by Rob-
erts and Torgerson [32] and Senn [41], baseline variables
of potential prognostic value were identified beforehand
and then fitted in the analysis. Literature and pilot studies
Table 1: Baseline demographic and clinical characteristics of included patients
Variable DIL group (n = 39) Values are mean (SD) or n 
(n%) within group
INJ group (n = 37) Values are mean (SD) or n 
(n%) within group
Age (years) 52 (7) 51 (6)
Female 26 (67%) 19 (51%)
Duration (months) 7 (4) 7 (4)
Left shoulder 16 (41%) 20 (54%)
Previous FS (other shoulder) 8 (21%) 9 (24%)
Patients with other shoulder problems 
previously
12 (31%) 21 (57%)
Patients who are smokers 10 (26%) 13 (35%)
Patients undergoing physiotherapy 5 (13%) 8 (22%)
Patients taking analgesics (daily) 11 (28%) 9 (24%)
Patients on sick leave 15 (39%) 25 (68%)Page 5 of 10
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assignment", "gender", "age", "baseline SPADI", "sick
leave at baseline", "baseline pain medication", "duration
of condition" and "previous shoulder problems". All var-
iables except "age" and "baseline SPADI" were dichot-
omized. Comparisons for ROM were performed by
independent t-tests.
Minimal clinical difference and sample size
A pilot study and previous studies were used to plan the
size of our study. We expected a between-patient standard
deviation (for ΔSPADI) of approximately 17 points. In a
previous study [23], a difference in SPADI score of 10
points or more was chosen as a minimal clinically signifi-
cant difference in shoulder pain and function. Published
data on this point is rather limited, but for practical rea-
sons, we adopted the same figure in our sample size calcu-
lations. With an alpha (p-value) of 5% and a power of
80%, this would result in a necessary sample size of 44
patients per group for a two-sided t-test. We judged that a
somewhat smaller sample size would be sufficient for our
purpose because we expected the regression analysis to
have greater statistical power to detect a treatment effect
than a usual t-test [42]. No interim analyses were planned
or conducted. All statistical analyses were carried out by
using the software package SPSS 13.0 for Windows® (SPSS,




The flow of participants through each stage of the trial is
reported by a CONSORT [44] flow diagram (Figure 1).
There was an unexpected restriction in treatment capacity,
which caused a waiting period for most patients before
any injections were given. Mean time from inclusion
(baseline assessment) to the first injection was received
was 8.2 weeks in the INJ group and 8.6 weeks in the DIL
group. 76 patients were included, of which 62 patients
received treatment according to protocol. The main rea-
son for lack of compliance was improvement of the con-
dition before any treatment had been given (n = 6), or
patients were not able to come to all three appointments
(n = 5). Mean baseline SPADI score for the patients who
were not given any injections because they felt their con-
dition had improved, was 53 (SD 18), and mean improve-
ment for these patients was 40 (SD 20). Follow-up data
for patients that were not given all injections were col-
lected at the same time point as if all planned injections
had been given. One patient moved to another part of the
country and was not available for follow-up. This patient
belonged to the DIL group and had a baseline SPADI
score of 40, which was adopted as the follow-up score for
this patient. For the 75 other patients, original follow-up
scores were used in the computations. One patient who
belonged to the INJ group was given 3 corticosteroid
injections by a different doctor before any of the planned
injections had been given. Our staff did not administer
any injections to this patient, who had a baseline SPADI
score of 93 and a follow-up score of 74.
Treatment effects
Both groups had significant improvement from baseline,
as could be expected for patients with this condition.
When baseline variables are adjusted for, the results indi-
cate a mean difference in ΔSPADI between treatment
groups of 3 points (Table 2). The observed difference is in
favor of the dilatation group, but is not significant (CI: -5





Coefficients 95% CI Coefficients 95% CI
Treatment
(INJ coded 0, DIL coded 1)
1 (-9 to 11) 3 (-5 to 11)
Gender
(female coded 0, male coded 1)
-1 (-11 to 9) 3 (-5 to 11)
Age
(years)
0.9 (0.1 to 1.7) 0.4 (-0.2 to 1.0)
Baseline SPADI score 0.7 (0.5 to 0.9) 0.9 (0.7 to 1.1)
Baseline pain medication
(< 1 tablet/day coded 0, 1 tablet/day or more coded 1)
3 (-8 to 14) -14 (-23 to -4)
Sick leave at baseline
("No" coded 0, "Yes" coded 1)
-1 (-11 to 9) -5 (-14 to 3)
Previous shoulder problems
(other than capsulitis)
("No" coded 0, "Yes" coded 1)
-3 (-13 to 7) -4 (-12 to 4)
Duration of condition at baseline
(< 6 months coded 0, 6 months or more coded 1)
-8 (-18 to 2) 0 (-8 to 7)Page 6 of 10
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large improvement in SPADI during treatment, according
to the simple regression analysis when variables are inves-
tigated one at a time. "Baseline SPADI score" and "Base-
line pain medication" appear as significant predictors
when all variables are analyzed simultaneously. The full
model explains 53% of the total variance in ΔSPADI.
Residuals are normally distributed and there is no evi-
dence of heteroscedasticity [43].
Details regarding mean (SD) values for SPADI and ROM
for baseline, change and follow-up scores are given in
Table 3. According to independent t-test comparisons
there are no statistically significant group differences for
any of the ROM measures.
At follow-up, five patients (13%) in the DIL group and
three patients (8%) in the INJ group were taking analge-
sics on a daily basis. Eleven patients (28%) in the DIL
group and twenty-three patients (62%) in the INJ group
were on sick leave.
Side effects and adverse reactions
Patients recorded pain intensity related to the injection
procedures. Most patients reported "no pain" or "discom-
fort" when describing the procedure. However, six
patients in the INJ group and five patients in the DIL
group felt that the injections were very painful. Other pos-
sible side effects were reported by 20 patients in the INJ
group and 14 patients in the DIL group. These were usu-
ally mild and lasted only for a few days. Most frequent
were complaints over flushing or disturbances in heat reg-
ulation (INJ group n = 13, DIL group n = 9). Two patients
in each group reported a minor loss of sensation and
motor control in their affected arm. Some patients com-
plained over loss of sleep, nausea or dizziness. One
patient in the DIL group developed a glenohumeral joint
infection which was identified 5 days after the last injec-
tion. He immediately underwent arthroscopic surgery and
was treated with infusions of cloxacillin for two weeks,
with a good result. His baseline SPADI score was 38, and
the score at follow-up was 50. One patient in the INJ
group developed breast cancer during the study period.
Formal statistical tests to compare adverse reactions in the
two groups were not made.
Discussion
Our study has not identified significant between-group
differences in main outcomes after treatment of the two
intervention groups. There may be several reasons for this
result. One may be that the hydrodilatation procedure
itself is of little or no additional value in improving
patient outcome. However, we cannot conclude that this
is the case, even though mean improvement was almost
similar in the two groups. Confidence intervals do not
exclude a difference in SPADI improvement larger than
the 10-point difference chosen beforehand to be the min-
imal clinically significant difference, meaning that an
important treatment effect from dilatation cannot be
excluded.
The procedure of hydrodilatation is thought to exert its
positive effects by improving glenohumeral mobility via
stretching or rupturing of the joint capsule. Gam et al. [15]
reported significant improvement in various ROM meas-
ures in the group treated with distension plus steroid com-
pared with the group treated with steroid alone. In the
present study, the measures of range of motion were
almost equal in the two groups at follow-up, a result
much in line with the findings of Corbeil et al. [27]. The
dilatation procedure may not be able to "release" the con-
tracted ligaments that cause restricted ROM. It is possible,
or perhaps even likely, that other structures than the walls
of the subscapular recess must rupture for such effects to
occur.
The observed lack of difference between the two groups
may stem from an inadequate procedure of dilatation. We




Mean (SD) or Mean (95% CI)
Follow-up
Mean (SD) or Mean (95% CI)
DIL INJ DIL INJ Group diff. DIL INJ Group diff.
SPADI 59 (20) 63 (20) -39 (21) -38 (22) -1 (-11 to 9) 20 (17) 26 (19) -6 (-14 to 2)
Passive abduction 31 (11) 31 (11) 14 (12) 14 (10) -1 (-6 to 4) 44 (12) 46 (13) -2 (-8 to 4)
Passive forward flexion 46 (17) 48 (14) 15 (18) 16 (13) -1 (-8 to 6) 61 (13) 65 (12) -3 (-9 to 2)
Passive ext. rotation 16 (14) 19 (13) 11 (14) 10 (11) 1 (-5 to 6) 27 (17) 29 (16) -2 (-10 to 5)
Passive int. rotation 32 (13) 34 (14) 13 (10) 15 (12) -2 (-7 to 3) 45 (12) 48 (15) -3 (-9 to 4)
Active abduction 55 (20) 57 (21) 31 (30) 26 (33) 5 (-10 to 19) 86 (34) 83 (37) 4 (-13 to 20)
Active forward flexion 89 (25) 87 (24) 28 (31) 29 (28) -1 (-15 to 12) 117 (28) 116 (30) 1 (-12 to 15)
Active ext. rotation 22 (16) 23 (15) 18 (16) 14 (12) 3 (-3 to 10) 39 (20) 37 (17) 3 (-6 to 11)
Active int. rotation 45 (16) 46 (15) 22 (16) 21 (15) 2 (-5 to 9) 68 (17) 66 (18) 1 (-7 to 9)Page 7 of 10
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volume given depending on joint capsule distensibility
before rupture. Other investigators have used larger
amounts of fluid, e.g. Buchbinder et al. [11] who used a
mean of 43 ml in the distension group. Our choice of pro-
cedure was based on the notion that continuing the injec-
tion when a rupture had occurred would give little
additional distension of the capsule, but instead cause
extra-articular deposition of injected material. Injection
volume in the INJ group was limited to 8–10 ml, but in
some cases rupture occurred even with this small volume.
There may have been a "dilatation" effect in some of the
patients in the INJ group, making it more difficult to iden-
tify possible group differences.
Several investigators recommending the hydrodilatation
procedure base these recommendations on results of stud-
ies where patients have been presented with a standard-
ized protocol of physiotherapy or manipulation [12-
14,16,19-21]. In our study, very few patients were under-
going physiotherapy during the trial. It is unclear whether
the specific effect of hydrodilatation depends on a combi-
nation with these interventions.
In most cases, adhesive capsulitis is a temporary condi-
tion. This makes it crucial to consider the time factor when
interpreting treatment results. In this study, patients with
shoulder pain for less than three months were not
included because we were afraid it would be difficult to
distinguish between typical bursitis and developing cap-
sulitis in this early phase. It may be that dilatation can
occur more easily in the early stages of the condition, and
the intervention may be of special value to these patients.
We do not know what the results would have been if
patients with acute frozen shoulder were also included in
the study.
A weakness of our study was an unexpected restriction in
treatment capacity, which caused a waiting period for
most patients before any injections were given. Baseline
assessments were made at inclusion, and mean time from
inclusion to treatment was about two months. Some
patients experienced spontaneous recovery in this period,
leaving a smaller margin for improvement as a result of
treatment. Also the waiting period may have reduced the
effect of dilatation due to more rigid structures in or
around the joint capsule.
The waiting period may also have led to the larger varia-
tion in patient outcome (ΔSPADI) than we had expected
(SDs were 21–22 compared to 17). On the other hand,
the regression model appears to explain a large propor-
tion (53%) of the variance in ΔSPADI, and it is our view
that the trial is not essentially undersized for this type of
study.
Patients were not blinded, and this may have introduced
bias, particularly since the primary outcome is a self-
reported form. Patients were told that they would all
receive corticosteroid injections, and some of them would
receive large volume injections in order to distend con-
tractions in tissues surrounding the joint. Information
was kept as balanced as possible, but some patients prob-
ably had the impression that hydrodilatation was the
more "sophisticated" approach. This may have biased
results in favor of this procedure.
The number of injections used in our study was based on
pilot studies and previous studies. The majority of
researchers have given only one injection. Some use three
injections, while Gam and colleagues [15] report giving
up to six injections. Although grossly underpowered,
Gam's study suggests that dilatation may be superior to
simple injection in improving ROM. Our choice was to
use a number that was closer to the "usual" approach, yet
was not essentially inferior to Gam's regimen. However,
using three injections instead of one may have been
unfortunate given the aim of the study, which was to iden-
tify treatment effects from hydrodilatation. It is likely that
a steroid injection may improve this condition. Repeating
injections may add to this, leaving a smaller margin for
improvement. Whether hydrodilatation effects cumulate
if injections are repeated is more unclear. It is possible
that the specific effects of hydrodilatation might have
been easier to identify if only one injection had been
given.
We have chosen to compare treatment effects by using the
method of a randomized controlled trial. Given the ran-
dom allocation of participants, we allow for the possibil-
ity that the treatment groups have important differences
in various respects. Using a regression model, we have
tried to control for variables that we expected to be rele-
vant. However, there may have been important group dif-
ferences at baseline that were not revealed or controlled
for.
Conclusion
In this study, we investigated treatment effects in patients
with adhesive capsulitis who received intraarticular injec-
tions either with or without a dilatation procedure. No
significant differences for selected outcomes between the
two treatment groups were recorded, but it is possible that
hydrodilatation may have an important treatment effect
in some cases. As for other interventions for shoulder dis-
orders, there is a need for future trials investigating the
effect of shoulder injections in patients with adhesive cap-
sulitis.Page 8 of 10
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